Pancreatic Cancer Research

ResearcherYokohama City UniversityActive in the last 2 years

Mariko Kamiya

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2867-423X; OpenAlex author ID A5103231574. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 3 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper · 2026: 2 papers

Papers 11

  1. Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19380-z↗
  2. ASO Author Reflections: Tissue Factor and Tumor Biology in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19510-7↗
  3. Significance of Preoperative Chemotherapy and Chemoradiotherapy in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17804↗
  4. Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients undergoing surgical resection of pancreatic ca… Co-author DOI 10.1007/s00423-024-03512-8↗
  5. Clinical Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgical Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16805↗
  6. Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-1 Adjuvant Chemotherapy After Pancreatec… Co-author DOI 10.21873/anticanres.17286↗
  7. Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.16327↗
  8. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-insti… Co-author DOI 10.21873/invivo.11780↗
  9. The Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Pancreatic Cancer. Co-author DOI 10.21873/invivo.11931↗
  10. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuva… Co-author DOI 10.4103/jcrt.jcrt_440_18↗
  11. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.12801↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masaaki Murakawa · 10 shared papers, 2018–2026 · strength 1.50
  2. Soichiro Morinaga · 10 shared papers, 2018–2026 · strength 1.50
  3. Makoto Ueno · 9 shared papers, 2018–2026 · strength 1.40
  4. Naoto Yamamoto · 9 shared papers, 2018–2025 · strength 1.26
  5. Shinnosuke Kawahara · 5 shared papers, 2023–2026 · strength 0.92
  6. Yohei Miyagi · 2 shared papers, 2026 · strength 0.74
  7. Shiro Koizume · 2 shared papers, 2026 · strength 0.74
  8. Yuto Kamioka · 4 shared papers, 2020–2026 · strength 0.66
  9. Satoshi Kobayashi · 5 shared papers, 2018–2026 · strength 0.65
  10. Toru Aoyama · 3 shared papers, 2023–2024 · strength 0.52
  11. Hiroshi Tamagawa · 5 shared papers, 2018–2024 · strength 0.51
  12. Toru Aoyama · 5 shared papers, 2018–2024 · strength 0.51
  13. Takashi Oshima · 3 shared papers, 2018–2024 · strength 0.32
  14. Masakatsu Numata · 3 shared papers, 2018–2020 · strength 0.25
  15. Manabu Morimoto · 3 shared papers, 2018–2020 · strength 0.25
  16. Kota Washimi · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.